Boston Scientific ( (BSX) ) has released its Q2 earnings. Here is a breakdown of the information Boston Scientific presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Boston Scientific Corporation is a leading global medical technology company that develops innovative solutions to improve patient health across various medical fields, including cardiovascular, respiratory, digestive, oncological, neurological, and urological diseases.
In its second quarter of 2025, Boston Scientific reported robust financial performance, with net sales reaching $5.061 billion, representing a significant increase of 22.8% compared to the previous year. The company also reported a GAAP net income of $797 million, or $0.53 per share, marking a substantial improvement from the prior year’s $324 million, or $0.22 per share.
Key highlights from the quarter include notable sales growth across its segments, with Cardiovascular sales up by 26.8% and MedSurg by 15.7%. Regionally, the U.S. saw a remarkable 30.7% increase in sales. The company also achieved strategic milestones, such as FDA approval for expanded use of its FARAPULSE PFA System and the acquisition of Intera Oncology and SoniVie Ltd.
Looking ahead, Boston Scientific anticipates continued growth, projecting full-year net sales growth of 18-19% on a reported basis and 14-15% on an organic basis. The company remains focused on leveraging its innovative portfolio and strategic acquisitions to drive long-term performance.
Overall, Boston Scientific’s strong quarterly performance and strategic initiatives position the company well for sustained growth in the competitive medical technology sector.